Glioblastoma Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Glioblastoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

Some of the key takeaways from the Glioblastoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years. 
• Glioblastoma companies working in the treatment market are J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biophar, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment 

• Emerging Glioblastoma therapies in the different phases of clinical trials are- JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.   
• The FDA has granted ONC201 Orphan Drug Designations for the treatment of glioblastoma and the treatment of malignant glioma, as well as Fast Track Designations for the treatment of adult recurrent high-grade gliomas caused by the H3 K27M mutation
• In December 2021, The FDA granted Fast Track Designation to the lead programme of Sapience Therapeutics, which is researching ST101 for the treatment of recurrent glioblastoma (GBM)
• In December 2021, Paxalisib as first-line therapy in patients with glioblastoma was the subject of a phase II clinical research that Kazia Therapeutics recently reported positive final results from (NCT03522298). The findings support paxalisib’s previously reported safety and effectiveness profile in treating this condition with a significant unmet need

Glioblastoma Overview

Glioblastoma (GBM), commonly known as a grade IV astrocytoma, is an aggressive brain tumour that grows quickly. Nearby brain tissue gets invaded, but it typically does not spread to distant organs. GBMs can develop from lower-grade astrocytomas or develop from new brain tumours.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

• JIN 001: J INTS BIO
• CT 179: Curtana Pharmaceuticals
• PRT3645: Prelude Therapeutics
• CD200AR L: OX2 Therapeutics
• ADI-PEG 20: Polaris Group
• Trabedersen: Oncotelic Therapeutics
• Selinexor: Karyopharm Therapeutics
• Onfekafuspalfa: Philogen
• AZD1390: AstraZeneca
• YTX7739: Yumanity Therapeutics
• CM93: Crimson Biopharm
• Berubicin: CNS Pharmaceuticals
• SurVaxM: MimiVax
• BPM31510: Berg, LLC
• ASC40: Ascletis
• Enzastaurin: Denovo Biopharma
• Marizomib: Celgene Corporation

Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Glioblastoma Pipeline Therapeutics Assessment

• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage and Product Type
• Glioblastoma Assessment by Route of Administration
• Glioblastoma By Stage and Route of Administration
• Glioblastoma Assessment by Molecule Type
• Glioblastoma by Stage and Molecule Type

DelveInsight’s Glioblastoma Report covers around 100+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are – Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others.

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
• Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies

Glioblastoma Pipeline Market Drivers

• Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers

• However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight    

• Coverage: Global
• Key Glioblastoma Companies: J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biophar, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others
• Key Glioblastoma Therapies: JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others
• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
• Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers 

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services